Eton Pharmaceuticals, Inc. Revenue
Eton Pharmaceuticals, Inc. (ETON) reported Revenue of $37.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $37.59M, a 98.59% increase year-over-year.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $24.27M, a 40.41% increase year-over-year.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $21.28M, a 82.72% increase year-over-year.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $22.46M, a 117.54% increase year-over-year.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $79.95M, a 104.94% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $39.01M, a 23.29% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $31.64M, a 48.90% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $21.25M, a 2.66% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.59M 10-Q · filed 2026-08-13 | $61.85M 10-Q · filed 2026-08-13 | $83.14M derived: sum of 3 quarters · filed 2026-08-13 | $105.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $24.27M 10-Q · filed 2026-05-14 | $45.55M derived: sum of 2 quarters · filed 2026-05-14 | $68.01M derived: sum of 3 quarters · filed 2026-05-14 | $86.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $21.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $43.74M derived: sum of 2 quarters · filed 2026-03-19 | $62.67M derived: sum of 3 quarters · filed 2026-08-13 | $79.95M 10-K · filed 2026-03-19 |
| 2025-09-30 | $22.46M 10-Q · filed 2025-11-06 | $41.39M derived: sum of 2 quarters · filed 2026-08-13 | $58.67M 10-Q · filed 2025-11-06 | $70.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $18.93M 10-Q · filed 2026-08-13 | $36.21M 10-Q · filed 2026-08-13 | $47.86M derived: sum of 3 quarters · filed 2026-08-13 | $58.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $17.28M 10-Q · filed 2026-05-14 | $28.93M derived: sum of 2 quarters · filed 2026-05-14 | $39.25M derived: sum of 3 quarters · filed 2026-05-14 | $48.33M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $21.97M derived: sum of 2 quarters · filed 2026-03-19 | $31.05M derived: sum of 3 quarters · filed 2026-03-19 | $39.01M 10-K · filed 2026-03-19 |
| 2024-09-30 | $10.32M 10-Q · filed 2025-11-06 | $19.40M derived: sum of 2 quarters · filed 2025-11-06 | $27.36M 10-Q · filed 2025-11-06 | $34.68M derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-06-30 | $9.07M 10-Q · filed 2025-08-07 | $17.04M 10-Q · filed 2025-08-07 | $24.35M derived: sum of 3 quarters · filed 2026-03-19 | $31.38M derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-03-31 | $7.97M 10-Q · filed 2025-05-13 | $15.28M derived: sum of 2 quarters · filed 2026-03-19 | $22.31M derived: sum of 3 quarters · filed 2026-03-19 | $34.30M derived: sum of 4 quarters · filed 2026-03-19 |
| 2023-12-31 | $7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $14.34M derived: sum of 2 quarters · filed 2026-03-19 | $26.34M derived: sum of 3 quarters · filed 2026-03-19 | $31.64M 10-K · filed 2026-03-19 |
| 2023-09-30 | $7.03M 10-Q · filed 2024-11-12 | $19.02M derived: sum of 2 quarters · filed 2024-11-12 | $24.33M 10-Q · filed 2024-11-12 | $32.83M derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-06-30 | $12.00M 10-Q · filed 2024-08-08 | $17.30M 10-Q · filed 2024-08-08 | $25.80M derived: sum of 3 quarters · filed 2025-03-18 | $29.02M derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-03-31 | $5.30M 10-Q · filed 2024-05-09 | $13.80M derived: sum of 2 quarters · filed 2025-03-18 | $17.02M derived: sum of 3 quarters · filed 2025-03-18 | $24.38M derived: sum of 4 quarters · filed 2025-03-18 |
| 2022-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $11.72M derived: sum of 2 quarters · filed 2025-03-18 | $19.07M derived: sum of 3 quarters · filed 2025-03-18 | $21.25M 10-K · filed 2025-03-18 |
| 2022-09-30 | $3.22M 10-Q · filed 2023-11-09 | $10.58M derived: sum of 2 quarters · filed 2023-11-09 | $12.75M 10-Q · filed 2023-11-09 | $18.85M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $7.36M 10-Q · filed 2023-08-10 | $9.53M 10-Q · filed 2023-08-10 | $15.63M derived: sum of 3 quarters · filed 2024-03-14 | $16.40M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $2.18M 10-Q · filed 2023-05-11 | $8.27M derived: sum of 2 quarters · filed 2024-03-14 | $9.04M derived: sum of 3 quarters · filed 2024-03-14 | $12.11M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $6.87M derived: sum of 2 quarters · filed 2024-03-14 | $9.94M derived: sum of 3 quarters · filed 2024-03-14 | $21.83M 10-K · filed 2024-03-14 |
| 2021-09-30 | $775.00K 10-Q · filed 2022-11-10 | $3.84M derived: sum of 2 quarters · filed 2022-11-10 | $15.74M 10-Q · filed 2022-11-10 | $15.82M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $3.07M 10-Q · filed 2022-08-11 | $14.96M 10-Q · filed 2022-08-11 | $15.04M derived: sum of 3 quarters · filed 2023-03-16 | $14.88M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $11.90M 10-Q · filed 2022-05-12 | $11.98M derived: sum of 2 quarters · filed 2023-03-16 | $11.82M derived: sum of 3 quarters · filed 2023-03-16 | $11.84M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$80.00K derived: sum of 2 quarters · filed 2023-03-16 | -$60.00K derived: sum of 3 quarters · filed 2023-03-16 | $39.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | -$161.00K 10-Q · filed 2021-11-16 | -$141.00K derived: sum of 2 quarters · filed 2021-11-16 | -$42.00K 10-Q · filed 2021-11-16 | $417.00K derived: sum of 4 quarters · filed 2021-11-16 |
| 2020-06-30 | $20.00K 10-Q · filed 2021-08-16 | $119.00K 10-Q · filed 2021-08-16 | $578.00K derived: sum of 3 quarters · filed 2021-08-16 | $578.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $99.00K 10-Q · filed 2021-05-13 | $558.00K derived: sum of 2 quarters · filed 2021-05-13 | $558.00K derived: sum of 3 quarters · filed 2021-05-13 | $558.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $459.00K 10-K · filed 2020-03-05 | $459.00K derived: sum of 2 quarters · filed 2020-11-12 | $459.00K derived: sum of 3 quarters · filed 2020-11-12 | $959.00K 10-K · filed 2022-03-16 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $500.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $500.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $500.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |